Our cases within drug development
Below, you can read more about our ongoing and completed assignments within drug development.
RISE accelerates the development of new antibiotics
To meet the global threat of resistant bacteria, we need a larger battery of possible treatments that can be used in a smart, strategic, and sustainable way. We also need treatments that are effective against resistant bacterial strains. New types of antibiotics with completely new mechanisms of action are an important piece of the puzzle.
Focus on customer needs yields outcomes when developing a new drug
Acute pulmonary hypertension, or high blood pressure in the lungs' pulmonary arteries, is a life-threatening condition that can develop in a variety of serious illnesses. The technology of Attgeno, a Swedish pharmaceutical business, is based on Karolinska Institutet's groundbreaking research on nitric oxide and circulatory physiology.
RISE gives small enterprises good advice in ADME studies
Antibiotic-resistant bacteria are a growing problem that puts certain drugs at risk of becoming ineffective. The Swedish company QureTech Bio's vision is to develop drugs to combat infectious diseases and the presence of antibiotic resistance.